{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:57:19Z","timestamp":1694116639149},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Taxane chemotherapy for esophageal cancer causes pneumonitis, not only by itself but also by radiation recall. This study aimed to clarify the risk of pneumonitis in patients with esophageal cancer who receive taxane therapy after chemoradiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The data of 129 patients with metastatic or recurrent esophageal cancer who initiated taxane therapy between September 2002 and June 2013 were retrospectively analyzed. Patient selection criteria were as follows: performance status \u22642, preserved organ functions, previous chemoradiotherapy with a radiation dose of \u226550 Gy, grade 0 or 1 pneumonitis at taxane initiation, and no concomitant malignancy. Logistic regression analysis was performed to identify risk factors for pneumonitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Patient characteristics were as follows: males\/females, 116\/13; median age, 63 years (range, 44 to 80 y); performance status of 0\/1\/2, 61\/60\/8; smoking history, 112 (88%); location of the primary tumor Ce\/Ut\/Mt\/Lt\/Ae 12\/30\/66\/20\/1; median radiation dose, 60 Gy; history of radiation pneumonitis, 39 (30%); history of other pulmonary disease, 4 (3%); and median duration between the last radiation therapy (RT) exposure and taxane initiation, 6.1 months (range, 1.0 to 71 mo). During the median observation period of 7.8 months from taxane initiation, the incidence of grade 2 and 3 pneumonitis was observed in 7 (5.4%) and 3 (2.3%) patients, respectively. No patient died of pneumonitis. The only independent risk factor for pneumonitis was a \u22644-month period between the last RT exposure and taxane initiation (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A short period between the last RT exposure and taxane initiation is an independent risk factor for pneumonitis development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000232","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T13:46:18Z","timestamp":1443620778000},"page":"41-45","source":"Crossref","is-referenced-by-count":4,"title":["Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Yoshihiro","family":"Kishida","sequence":"first","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[{"name":"Medical Oncology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[{"name":"Gastrointestinal Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230905","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R4-20230905","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jjco\/hyt048","article-title":"Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II-III esophageal carcinoma","volume":"43","author":"Kato","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-010-1422-x","article-title":"A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy","volume":"67","author":"Kato","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.1996.14.5.1649","article-title":"Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study","volume":"14","author":"Kunitoh","year":"1996","journal-title":"J Clin Oncol"},{"key":"R8-20230905","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000227707","article-title":"Phase II study of 3-h infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group","volume":"54","author":"Furuse","year":"1997","journal-title":"Oncology"},{"key":"R9-20230905","first-page":"1931","article-title":"Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer","volume":"4","author":"Choy","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000074475","article-title":"Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer","volume":"65","author":"Yasuda","year":"2003","journal-title":"Oncology"},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000079481","article-title":"Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments","volume":"66","author":"Yasuda","year":"2004","journal-title":"Oncology"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1378\/chest.129.4.1031","article-title":"A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"R13-20230905","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1378\/chest.110.1.289","article-title":"Pulmonary infiltrates following administration of paclitaxel","volume":"110","author":"Ramanathan","year":"1996","journal-title":"Chest"},{"key":"R15-20230905","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1177\/106002809703101205","article-title":"Paclitaxel-induced acute bilateral pneumonitis","volume":"31","author":"Khan","year":"1997","journal-title":"Ann Pharmacother"},{"key":"R16-20230905","first-page":"2476","article-title":"Pulmonary changes in patients with lymphoma who receive paclitaxel","volume":"15","author":"Ayoub","year":"1997","journal-title":"J Clin Oncol"},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","article-title":"Phase I study of docetaxel with concomitant thoracic radiation therapy","volume":"16","author":"Mauer","year":"1998","journal-title":"J Clin Oncol"},{"key":"R18-20230905","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0959-8049(00)00341-5","article-title":"Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I\/II dose-escalating study","volume":"36","author":"Thomas","year":"2000","journal-title":"Eur J Cancer"},{"key":"R19-20230905","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1054\/bjoc.2001.2071","article-title":"Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)","volume":"85","author":"Wang","year":"2001","journal-title":"Br J Cancer"},{"key":"R20-20230905","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.10263","article-title":"Severe interstitial pneumonitis associated with docetaxel administration","volume":"94","author":"Read","year":"2002","journal-title":"Cancer"},{"key":"R21-20230905","first-page":"563","article-title":"Acute interstitial pneumopathy associated with docetaxel hypersensitivity","volume":"27","author":"Karacan","year":"2004","journal-title":"Onkologie"},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00128071-200001020-00006","article-title":"Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management","volume":"1","author":"Yeo","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"R23-20230905","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-8140(01)00328-0","article-title":"Characterizing the phenomenon of radiation recall dermatitis","volume":"59","author":"Camidge","year":"2001","journal-title":"Radiother Oncol"},{"key":"R24-20230905","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ctrv.2005.07.008","article-title":"Radiation recall: a well recognized but neglected phenomenon","volume":"31","author":"Azria","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R25-20230905","first-page":"209","article-title":"An ambiguous phenomenon of radiation and drugs: recall reactions","volume":"30","author":"Caloglu","year":"2007","journal-title":"Onkologie"},{"key":"R26-20230905","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"key":"R27-20230905","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004728-198402000-00003","article-title":"Radiation-induced plumonary change: CT findings","volume":"8","author":"Libshitz","year":"1984","journal-title":"J Comput Assist Tomogr"},{"key":"R29-20230905","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1995.13.2.534","article-title":"Pneumonitis related to treatment with paclitaxel","volume":"13","author":"Goldberg","year":"1995","journal-title":"J Clin Oncol"},{"key":"R30-20230905","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1008226416896","article-title":"Docetaxel and interstitial pulmonary injury","volume":"8","author":"Merad","year":"1997","journal-title":"Ann Oncol"},{"key":"R31-20230905","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000011873","article-title":"Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy","volume":"55","author":"Fujimori","year":"1998","journal-title":"Oncology"},{"key":"R32-20230905","first-page":"199","article-title":"Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases","volume":"15","author":"Etienne","year":"1998","journal-title":"Rev Mal Respir"},{"key":"R33-20230905","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1023\/A:1008377819875","article-title":"Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma","volume":"10","author":"Dunsford","year":"1999","journal-title":"Ann Oncol"},{"key":"R34-20230905","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/ijgc-00009577-200602001-00071","article-title":"Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature","volume":"16","author":"Ostoros","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R35-20230905","first-page":"635","article-title":"Pneumonitis related to docetaxel: case report and review of the literature","volume":"23","author":"Alsamarai","year":"2009","journal-title":"In Vivo"},{"key":"R36-20230905","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiol.2301021226","article-title":"Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance","volume":"230","author":"Aoki","year":"2004","journal-title":"Radiology"},{"key":"R37-20230905","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1378\/chest.128.3.1448","article-title":"Positron emission tomography demonstrates radiation-induced change to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy","volume":"128","author":"Hassaballa","year":"2005","journal-title":"Chest"},{"key":"R38-20230905","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-8140(03)00119-1","article-title":"Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study","volume":"67","author":"Rancati","year":"2003","journal-title":"Radiother Oncol"},{"key":"R39-20230905","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jrr\/rrv019","article-title":"Stereotactic body radiotherapy for stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis","volume":"56","author":"Inoue","year":"2015","journal-title":"J Radiat Res"},{"key":"R40-20230905","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"Semb","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201801000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:39:00Z","timestamp":1693957140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201801000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000232","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}